Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;63(6):1248-1257.
doi: 10.1007/s00125-020-05120-9. Epub 2020 Mar 9.

Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus

Sunny S Singh  1   2 , Mardin Rashid  1 , Aloysius G Lieverse  2 , Florian Kronenberg  3 , Claudia Lamina  3 , Monique T Mulder  1 , Yolanda B de Rijke  4 , Eric J G Sijbrands  1 , Mandy van Hoek  5
Affiliations

Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus

Sunny S Singh et al. Diabetologia. 2020 Jun.

Abstract

Aims/hypothesis: Microvascular disease in type 2 diabetes is a significant cause of end-stage renal disease, blindness and peripheral neuropathy. The strict control of known risk factors, e.g. lifestyle, hyperglycaemia, hypertension and dyslipidaemia, reduces the incidence of microvascular complications, but a residual risk remains. Lipoprotein (a) [Lp(a)] is a strong risk factor for macrovascular disease in the general population. We hypothesised that plasma Lp(a) levels and the LPA gene SNPs rs10455872 and rs3798220 are associated with the incident development of microvascular complications in type 2 diabetes.

Methods: Analyses were performed of data from the DiaGene study, a prospective study for complications of type 2 diabetes, collected in the city of Eindhoven, the Netherlands (n = 1886 individuals with type 2 diabetes, mean follow-up time = 6.97 years). To assess the relationship between plasma Lp(a) levels and the LPA SNPs with each newly developed microvascular complication (retinopathy n = 223, nephropathy n = 246, neuropathy n = 236), Cox proportional hazards models were applied and adjusted for risk factors for microvascular complications (age, sex, mean arterial pressure, non-HDL-cholesterol, HDL-cholesterol, BMI, duration of type 2 diabetes, HbA1c and smoking).

Results: No significant associations of Lp(a) plasma levels and the LPA SNPs rs10455872 and rs3798220 with prevalent or incident microvascular complications in type 2 diabetes were found. In line with previous observations the LPA SNPs rs10455872 and rs3798220 did influence the plasma Lp(a) levels.

Conclusions/interpretation: Our data show no association between Lp(a) plasma levels and the LPA SNPs with known effect on Lp(a) plasma levels with the development of microvascular complications in type 2 diabetes. This indicates that Lp(a) does not play a major role in the development of microvascular complications. However, larger studies are needed to exclude minimal effects of Lp(a) on the development of microvascular complications.

Keywords: LPA; Lp(a); Microvascular complications; Nephropathy; Neuropathy; Retinopathy; SNP; Spline; rs10455872; rs3798220.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves for the percentage of the study population who developed retinopathy (a), nephropathy (b) or neuropathy (c) during follow-up according to Lp(a) level
See this image and copyright information in PMC

References

    1. Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339–e349. doi: 10.1016/S2214-109X(13)70113-X. - DOI - PubMed
    1. Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: Prevention and management. J Res Med Sci. 2015;20(11):1112–1120. doi: 10.4103/1735-1995.172845. - DOI - PMC - PubMed
    1. Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J. 2006;82(964):95–100. doi: 10.1136/pgmj.2005.036137. - DOI - PMC - PubMed
    1. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–437. doi: 10.1016/S2213-8587(17)30104-3. - DOI - PubMed
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi: 10.1056/NEJMoa0806470. - DOI - PubMed

Publication types